A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Dana-Farber Cancer Institute
St. Jude Children's Research Hospital
City of Hope Medical Center
Children's Cancer Group, China
Dartmouth-Hitchcock Medical Center
Memorial Sloan Kettering Cancer Center
Alliance for Clinical Trials in Oncology
Radiation Therapy Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Alliance for Clinical Trials in Oncology
St. Jude Children's Research Hospital
BTG International Inc.
Gustave Roussy, Cancer Campus, Grand Paris
South Plains Oncology Consortium
National Institute of Allergy and Infectious Diseases (NIAID)
SWOG Cancer Research Network
National Institute of Allergy and Infectious Diseases (NIAID)
M.D. Anderson Cancer Center
Takeda
M.D. Anderson Cancer Center
Therapeutic Advances in Childhood Leukemia Consortium
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Texas Southwestern Medical Center
Masonic Cancer Center, University of Minnesota
Northwestern University
M.D. Anderson Cancer Center
Children's Oncology Group
Children's Hospital of Philadelphia
University of Texas Southwestern Medical Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Radiation Therapy Oncology Group
Masonic Cancer Center, University of Minnesota
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
St. Jude Children's Research Hospital
UNC Lineberger Comprehensive Cancer Center
Dana-Farber Cancer Institute
Massachusetts General Hospital
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
Massachusetts General Hospital
Trans Tasman Radiation Oncology Group
University of Miami